Hypoxia‐induced exosomal PKM2 not only promotes glycolysis in NSCLC cells to produce reductive metabolites, thus neutralizing cisplatin‐induced ROS, but also reprograms CAFs to create an acidic microenvironment that promotes cisplatin resistance[176] (Figure 4). The gene discussed is PKM; the disease is non-small cell lung carcinoma.